Epidarex Capital (Epidarex), a transatlantic life science venture firm, has closed Epidarex Capital III UK LP at GBP102.1 million. The Fund will build new life science companies based on world-class research and innovation from emerging hubs across the UK, including spinouts from highly regarded universities. Typical initial investments will range
Nordic lower mid-market growth and buyout group Priveq, which invests in companies within the consumer, healthcare, IT and software sectors, has closed its sixth fund on SEK 2.5 billion. The fund’s investors include existing and new Nordic, European and North American investors, including public and private pension funds, insurance companies,
Hoxton Ventures has held the final close of its second fund, an early stage European VC fund, which includes seed investments in Babylon Health, Deliveroo and Darktrace. Existing investors in Hoxton’s first fund have invested in the second fund as well, alongside capital from new British, Swiss and US institutional
Growth equity investment firm FTV Capital (FTV) has closed its sixth and largest fund to date, FTV VI, at ts hard cap of USD1.2 billion in capital commitments from existing and new limited partners. Over its 22-year history, FTV has raised nearly USD4 billion and invested in 114 innovative, high-growth companies
German independent asset manager Prime Capital AG has reached a EUR202 million first closing on its Prime Green Energy Infrastructure Fund, its first commingled product in the infrastructure space. The Fund focuses on wind-powered energy assets in the Nordic countries, with no reliance on government support and with the lowest cost
The Luxembourg-domiciled euro denominated structure closed with EUR 260 million of commitments on 27 March, surpassing its EUR200 million target. Neuberger Berman launched the Crossroads funds of funds platform in the early 1980s, with the aim of constructing diversified private equity portfolios across asset classes, strategies and geographies. The new
Zürich-based private equity firm Evoco has held a first close of its third fund, Evoco TSE III SCSp at EUR93 million, representing more than 50 per cent of the target size of its third institutional fund. Domiciled in Luxembourg, Evoco TSE III SCSp has a target size of EUR150 million.
Spanish biotech VC firm Ysios Capital has held a first close of its third fund, Ysios BioFund III, at EUR155 million. The fund has a final target size of EUR200 million. Ysios Capital is the largest venture capital firm in Spain specialised in biotechnology with EUR346 million under management through
Wing Venture Capital announced today that it has raised Wing Three, a USD450 million pool of capital dedicated to early stage investing and long-term company-building in enterprise technology. Like the firm’s predecessor funds, Wing Three has the backing of the venture world’s most sophisticated institutional investors. In a sign of the
Petra Capital Partners, based in Nashville, has completed fundraising on Petra Growth Fund IV (PGF IV) with USD208 million of capital available to invest. The fund targets healthcare, business, and technology-enabled services companies and is structured as a small business investment company (SBIC) licensed by the US Small Business Administration.
12 November, 2026 – 5:00 pm
12 November, 2026 – 8:00 am
12 February, 2026 – 8:00 am
12 February, 2026 – 5:00 pm
